Glaukos Corporation (GKOS) 是一家上市公司 屬於 醫療保健 板塊,經營於 Medical - Devices 產業. 公司總部位於 Aliso Viejo, CA, 美国. 現任CEO為 Thomas William Burns.
GKOS 擁有 IPO日期為 2015-06-25, 995 名全職員工, 在 NYSE, 市值為 $7.03B.
Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company headquartered in San Clemente, California, specializing in innovative therapies for glaucoma, corneal disorders, and retinal diseases. The company's flagship products include the iStent family of micro-bypass stents—iStent, iStent inject, and iStent inject W—which are implanted during cataract surgery to improve aqueous humor outflow and treat mild-to-moderate open-angle glaucoma. Its pipeline includes iStent Infinite, a three-stent system designed for standalone use in refractory glaucoma patients, and iDose TR, a targeted injectable implant that delivers therapeutic medication levels. Glaukos markets its products globally through a combination of direct sales operations and distributor networks. Founded in 1998, the company continues to advance minimally invasive surgical solutions for serious eye conditions.